We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Blood Pressure Medications on Metabolism

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00642434
First Posted: March 25, 2008
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Kathleen Colleran, University of New Mexico
  Purpose

The purpose of this study is to determine if there are differences, (benefits) between carvedilol and metoprolol in the treatment of HTN in patients with type 2 diabetes. Specifically we will be looking at differences in blood pressure and blood sugar control, endothelial function, inflammation, oxidative stress and coagulation.

Subjects will be randomized to one of the two beta-blockers and followed for 5 months. Each subject will undergo 4 inpatient studies where an oral glucose tolerance test will be done, Inflammatory and oxidative stress markers will be measured. Endothelial function will be measured using brachial artery ultrasound and laser skin Doppler


Condition Intervention Phase
Diabetes Drug: carvedilol Drug: metoprolol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension

Resource links provided by NLM:


Further study details as provided by Kathleen Colleran, University of New Mexico:

Primary Outcome Measures:
  • change in endothelial function [ Time Frame: 5 months ]

Enrollment: 21
Study Start Date: January 2004
Study Completion Date: July 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
study drug
Drug: carvedilol
variable
Active Comparator: 2
study drug
Drug: metoprolol
variable

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • not enrolling

Exclusion Criteria:

  • not enrolling
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00642434


Locations
United States, New Mexico
UNMHSC
Albquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
  More Information

Responsible Party: Kathleen Colleran, Professor of Medicine, University of New Mexico
ClinicalTrials.gov Identifier: NCT00642434     History of Changes
Other Study ID Numbers: UNM04094
First Submitted: March 21, 2008
First Posted: March 25, 2008
Last Update Posted: October 12, 2017
Last Verified: August 2011

Keywords provided by Kathleen Colleran, University of New Mexico:
diabetes blood pressure oxidative stress

Additional relevant MeSH terms:
Metoprolol
Carvedilol
Anti-Arrhythmia Agents
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists